CoChat

Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation

Keck, Paul E., Hsu, Hai-An, Papadakis, Kelly, Russo, John · 2009 · Clinical Neuropharmacology
Cited by 51

The DOI matches its Crossref record.

Abstract

OBJECTIVE: Evaluate the efficacy and tolerability of memantine (20, 30, and 40 mg/d) in the acute treatment of adults with bipolar I disorder hospitalized for mania. METHODS: This multicenter, open-label, pilot trial included adults with bipolar I disorder (manic or mixed episode, with and without psychotic features). Patients were assigned to 21 days of treatment: cohort 1, 20 mg/d (range, 20-30 mg/d); cohort 2, 30 mg/d (range, 30-40 mg/d); cohort 3, 40 mg/d (range, 30-50 mg/d). Efficacy measures included the Young Mania Rating Scale (YMRS) and the Mania Rating Scale (>or=50% reduction in total score from baseline). The change from baseline was also assessed using the Positive and Negative Syndrome Scale in patients with psychiatric symptoms, Positive and Negative Syndrome Scale-Excited Component, Clinical Global Impression Severity and Improvement scores, and Montgomery Asberg Depression Rating Scale. RESULTS: A total of 35 patients were enrolled; 33 patients received at least 1 dose of memantine and had at least 1 postbaseline assessment using YMRS. Greatest improvement occurred in cohort 1 where half of the patients responded to memantine based on YMRS and Mania Rating Scale. At day 21, a response was observed in all patient cohorts. Treatment-emergent adverse events were reported in 19 patients (54.3%). The most frequently reported adverse events (>or=4 patients) included constipation, nausea, and headache. CONCLUSIONS: The response to memantine combined with its tolerability support conducting large-sized randomized controlled trials to investigate further the use of memantine monotherapy in the treatment of mania.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wnf.0b013e318184fae2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 10

  1. Mitchell, 2004, Major advances in bipolar disorder., Med J Aust, 181, 207, 10.5694/j.1326-5377.2004.tb06238.x · DOI
  2. Schiffer, 2002, Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?, Mol Neurobiol, 25, 191, 10.1385/MN:25:2:191 · DOI
  3. Michael, 2003, Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex., Psychopharmacology (Berl), 168, 344, 10.1007/s00213-003-1440-z · DOI · Paper page
  4. Bown, 2003, Attenuation of N-methyl-d-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers., Neuroscience, 117, 949, 10.1016/S0306-4522(02)00743-1 · DOI
  5. Tsapakis, 2002, Glutamate and psychiatric disorders., Adv Psychiatr Treat, 8, 189, 10.1192/apt.8.3.189 · DOI
  6. Rogoz, 2002, Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats., Neuropharmacology, 42, 1024, 10.1016/S0028-3908(02)00055-2 · DOI · Paper page
  7. Muller-Oerlinghausen, 2002, Bipolar disorder., Lancet, 359, 241, 10.1016/S0140-6736(02)07450-0 · DOI · Paper page
  8. Sachs, 2003, Unmet clinical needs in bipolar disorder., J Clin Psychopharmacol, 23, S2, 10.1097/01.jcp.0000084038.22282.47 · DOI
  9. Keck, 2003, The management of acute mania: encouraging results from clinical trials need to be replicated in practice., Br Med J, 327, 1001, 10.1136/bmj.327.7422.1002 · DOI
  10. Baldessarini, 2003, Assessment of treatment response in mania: commentary and new findings., Bipolar Disord, 5, 79, 10.1034/j.1399-5618.2003.00020.x · DOI

Cited by

See all 51

Metadata

Authors
Keck, P. E., Hsu, H.-A., Papadakis, K., & Russo, J.
Venue
Clinical Neuropharmacology
Published
2009-07
Volume
32
Issue
4
Pages
199-204
ISSN
0362-5664 (ISSN-L)
OpenAlex
W2001572391
Cited by
51
References
0
FWCI
2.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation. https://app.cochat.ai/papers/10.1097/wnf.0b013e318184fae2
The paper
Keck, P. E., Hsu, H.-A., Papadakis, K., & Russo, J. (2009). Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e318184fae2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.